Literature DB >> 3733376

Phase II study of 4'-deoxydoxorubicin in advanced colorectal cancer.

G Falkson, D A Vorobiof.   

Abstract

Thirty-three patients with advanced colorectal cancer were entered on a phase II study of 4'-deoxydoxorubicin (esorubicin) (30-35 mg/m2 q 3 weekly). Objective response was documented in 4 of 25 previously untreated patients and in none of 8 previously treated patients. Toxicity was acceptable with grade 3 or 4 leukopenia occurring in 8 patients. Complete alopecia occurred only in 4 patients and gastro-intestinal toxicity was mild. A significant decrease (greater than 10%) of the left ventricular ejection fraction occurred in 8/23 patients who received greater than 2 courses of treatment.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3733376     DOI： 10.1007/bf00194597

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  6 in total

1.  Synthesis and antitumour activity of new daunorubicin and adriamycin analogues.

Authors:  F Arcamone; L Bernardi; B Patelli; P Giardino; A Di Marco; A M Casazza; C Soranzo; G Pratesi
Journal:  Experientia       Date:  1978-10-15

2.  Left ventricular regional wall motion assessment by multigated and end-diastolic, end-systolic gated radionuclide left ventriculography.

Authors:  R D Okada; G M Pohost; A B Nichols; K A McKusick; H W Strauss; C A Boucher; P C Block; S V Rosenthal; R E Dinsmore
Journal:  Am J Cardiol       Date:  1980-06       Impact factor: 2.778

3.  Phase I and clinical pharmacological evaluation of 4'-deoxydoxorubicin in patients with advanced cancer.

Authors:  G F Stanton; V Raymond; R E Wittes; P Schulman; D Budman; R Baratz; L Williams; G R Petroni; N L Geller; C Hancock
Journal:  Cancer Res       Date:  1985-04       Impact factor: 12.701

4.  Variation in left ventricular ejection fraction determination at rest and during exercise.

Authors:  A van Aswegen; C P Herbst; M G Lötter; A C Otto; P H Kleynhans; P C Minnaar
Journal:  S Afr Med J       Date:  1983-06-04

5.  New doxorubicin analogs active against doxorubicin-resistant colon tumor xenografts in the nude mouse.

Authors:  F C Giuliani; N O Kaplan
Journal:  Cancer Res       Date:  1980-12       Impact factor: 12.701

6.  Phase I trial of esorubicin (4'deoxydoxorubicin).

Authors:  H S Garewal; A Robertone; S E Salmon; S E Jones; D S Alberts; R Brooks
Journal:  J Clin Oncol       Date:  1984-09       Impact factor: 44.544
  6 in total
  3 in total

1.  Clinical cardiotoxicity of esorubicin (4'-deoxydoxorubicin,DxDx): prospective studies with serial gated heart scans and reports of selected cases. A Cancer and Leukemia Group B report.

Authors:  Q S Ringenberg; K J Propert; H B Muss; R B Weiss; R L Schilsky; C Modeas; M C Perry; L Norton; M Green
Journal:  Invest New Drugs       Date:  1990-05       Impact factor: 3.850

2.  Esorubicin (deoxydoxorubicin) has low grade activity in malignant melanoma. Results of an Eastern Cooperative Oncology Group study (EST 2685).

Authors:  H Hochster; M Hunt; M Green; D Parkinson; T Smith
Journal:  Invest New Drugs       Date:  1990-08       Impact factor: 3.850

Review 3.  Fatal esorubicin-induced cardiomyopathy: report of a case and review of the literature.

Authors:  L F Diehl; A Banks; W Carter; M A Klein; H B Muss; R B Weiss
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.